Table 1.
Clinical characteristics of colorectal cancer patients who underwent laparoscopic surgery (n = 192)
| Characteristic | Values |
|---|---|
| Age (yr) | 65.57 ± 9.88 |
| Sex | |
| Male | 119 (62.0%) |
| Female | 73 (38.0%) |
| BMI (kg/m2) | 24.11 ± 3.05 |
| < 25 | 131 (68.2%) |
| ≥ 25 | 61 (31.8%) |
| Cancer location | |
| Ascending colon | 26 (13.5%) |
| Hepatic flexure | 16 (8.3%) |
| Splenic flexure | 7 (3.6%) |
| Descending colon | 3 (1.6%) |
| Sigmoid colon | 66 (34.4%) |
| Rectum | 74 (38.5%) |
| T stage | |
| T0 | 9 (4.7%) |
| T1 | 64 (33.3%) |
| T2 | 28 (14.6%) |
| T3 | 78 (40.6%) |
| T4 | 13 (6.8%) |
| N stage | |
| N0 | 139 (72.4%) |
| N1 | 42 (21.9%) |
| N2 | 11 (5.7%) |
| Tumor size (cm) | 3.46 ± 2.32 |
| Preoperative laboratory study | |
| CEA (ng/ml) | 5.45 ± 20.21 |
| Albumin (g/dl) | 4.24 ± 0.38 |
| Image system | |
| Stryker (1588 AIM camera system) | 148 (77.1%) |
| Storz (IMAGE1 S™) | 38 (19.8%) |
| Olympus (CLV-S200-IR) | 6 (3.1%) |
| Fluorescence lymph node mapping | |
| Success | 136 (70.8%) |
| Fail | 56 (29.2%) |
| Injected ICG dosage (mg) | |
| > 12 | 3 (1.6%) |
| 1–12 | 10 (5.2%) |
| 0.5–1 | 75 (39.1%) |
| 0.3–0.5 | 32 (16.7%) |
| < 0.3 | 72 (37.5%) |
BMI body mass index, CEA carcinoembryonic antigen, ICG Indocyanine green